This effective medicine is composed of Dutasteride as the main active component. It is a synthetic 4-azasteroid compound. This drug binds to isoenzymes 1 and 2 of 5 alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5 alpha-dihydrotestosterone. The reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type alpha-reductase isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also active in the skin and the liver.
This mentioned drug is indicated in men to treat the symptoms of an enlarged prostate i.e. benign prostatic hyperplasia. Avodart reduces the size of the enlarged prostate. It also relieves symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently. It may also decrease the need for surgery to treat BPH. It is not approved for the prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer.
This mentioned medicine is indicated for the treatment of benign prostatic hyperplasia also known as an enlarged prostate. Avodart belongs to a class of medication called 5-alpha reductase inhibitors. Male hormone dihydrotestosterone is primarily responsible for the development and enlargement of the prostate gland. The active component of this medicine blocks the 5-alpha reductase enzyme and prevents excessive DHT production in the prostate gland. It delays the progression of an enlarged prostate and improves symptoms of BPH.
This medicine is composed as the conventional tablet form in a dosage as given below:
- 0.5 mg: It is advisable to take with or without food as directed by the doctor, usually once a day
This medicine is not recommended in women or children.